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ABSTRACT 
Objective: The main aim of this study was to develop a rapid, simple and selective validated high-performance thin-layer chromatographic (HPTLC) 
method with UV detection for the estimation of alprazolam and fluoxetine HCl from spiked rat plasma.  
Methods: In this method, a mixture of acetonitrile and chloroform (2:4 v/v) was employed as the solvent for extraction of alprazolam and 
fluoxetine HCl from spiked rat plasma samples with good sample recovery. The separation was achieved on a 20 cm x10 cm TLC plate precoated 
with silica gel 60F254, the 250μm thickness on aluminium sheets employing a mobile phase consisting of ethyl acetate: toluene: methanol: ammonia 
(4:3:1:0.1v/v/v/v). The densitometric evaluation was performed at 230 nm. The developed method was validated as per the recommendations of 
USFDA Guidance for Industry: Bioanalytical Method Validation. 
Results: The Rf value were observed at 0.48±0.04 and 0.17±0.02 for alprazolam and fluoxetine HCl respectively. The calibration curves were linear in 
the range of 40-100 ng/μl for both drugs with regression coefficients (r2
Conclusion: In the proposed method, the rapid, single step extraction of drugs from plasma samples coupled with the simple HPTLC-UV 
chromatographic conditions makes the method cost effective and suitable for analysis of a large number of binary samples of alprazolam and 
fluoxetine HCl in plasma. 
) of 0.9910 and 0.9932 for alprazolam and fluoxetine HCl respectively. In the 
intraday and interday precision study, the % CV was less than 15. Results of recovery studies prove the extraction efficiency of the proposed method. 
Stability data indicated that both alprazolam and fluoxetine HCl were stable in plasma after three freeze-thaw cycles and upon storage at -20 °C for 1 w. 
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INTRODUCTION 
Alprazolam (fig. 1), chemically known as 8-Chloro-1-methyl-6-
phenyl-4H [1, 2, 4] triazole [4, 3a] [1, 4]-benzodiazepine, is a 
synthetic, short-acting anxiolytic of the benzodiazepine class and 
used to treat anxiety disorders, panic attacks and anxiety caused by 
depression. It acts by binding to specific sites on the GABAA
Fluoxetine HCl (fig. 1) is (±)-N methyl-3-phenyl-3-[(α, α, α-
trifluoro-p tolyl) oxy] propylamine hydrochloride, a selective 
serotonin reuptake inhibitor (SSRI) antidepressant. It is used to 
treat major depression (including paediatric depression), 
obsessive-compulsive disorder (in both adult and paediatric 
populations), bulimia nervosa (an eating disorder), anorexia 
nervosa, panic disorder, premenstrual dysphoric disorder (PMDD) 
and Parkinson’s disease [1]. 
 
receptor, hence possesses anxiolytic, sedative, hypnotic, skeletal 
muscle relaxant, anticonvulsant and amnestic properties.  
 
 
Fig. 1: Chemical structures of Alprazolam and Fluoxetine HCl 
 
Combined administration of alprazolam and fluoxetine HCl resulted 
in an approximate 30% increase in alprazolam plasma 
concentration relative to plasma concentration following the 
administration of alprazolam alone. Also psychomotor decrements 
increased when fluoxetine was administered with alprazolam 
relative to administration of alprazolam alone. 
Several methods are reported for the estimation of alprazolam 
employing HPLC-UV, LC-MS/MS, and GC-MS individually and in 
combination with other drugs [2-4]. Literature survey also reveals 
different methods like LC-MS/MS, RP-HPLC with fluorescence 
detection and pre-column derivitisation for UV-sensitivity 
enhancement for estimation of fluoxetine HCl individually and in 
combination with other drugs [5-8]. Few HPTLC methods are also 
reported for estimation of alprazolam and fluoxetine HCl 
individually and in combination with other drugs [9-12]. Also, a 
single HPLC and HPTLC method is reported for the simultaneous 
estimation of alprazolam and fluoxetine HCl in tablet formulation 
[13]. However, no HPTLC method has been reported so far for the 
simultaneous estimation of alprazolam and fluoxetine HCl in plasma. 
Therefore, it was thought desirable to develop a simple, accurate, 
cheap and fast procedure that could be applied for the simultaneous 
determination of alprazolam and fluoxetine in plasma with protein 
precipitation and liquid-liquid extraction as the only sample 
preparation step involved prior to HPTLC analysis.  
MATERIALS AND METHODS 
Chemicals and reagents 
Active pharmaceutical ingredient (API), working standards of 
alprazolam and fluoxetine HCl, were obtained from Aarti Drugs Pvt 
Ltd., India. Ethyl acetate, toluene, methanol, ammonia AR grade 
ammonia grade were obtained from Fisher Scientific, India and 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 3, 2016 
Thomas et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 3, 147-151 
 
148 
Himedia Lab Pvt. Ltd, India. TLC plates precoated with silica gel 
60F254 with 250μm thickness on aluminium sheets were purchased 
from Merck India Pvt. Ltd., India. Rat plasma used for the research 
work was obtained from albino wistar rats purchased from National 
Toxicology Centre, Pune, India. 
Instrument 
Camag TLC plates with precoated silica gel plate 60F254
Merck TLC plates coated with silica gel 60 F
 (20 x 10 
cm), 250 μm thickness (E. Merck, Darmstadt, Germany) was used as 
stationary phase. The sample application was done by Camag 100 μl 
syringe using Camag Linomat 5 applicator. The sample was sprayed 
in the form of narrow bands of 6 mm length at a constant rate 
0.2μl/s. Linear ascending development was carried out in 20 x 10 
cm twin trough glass chamber (Camag, Muttenz, Switzerland). The 
densitometric scanning was performed using Camag TLC scanner 3 
supported by win CATS software (Version 1.4.3.6336 Camag). 
Evaluation of chromatograms was done by using peak areas.  
Methods 
Preparation of Stock solution, Calibration standards (CS) and 
quality control (QC) samples  
A stock solution of concentration 1000 µg/ml each of alprazolam 
and fluoxetine HCl were prepared in methanol.  In 10 ml centrifuge 
tubes, 1.0 ml of stock solution of alprazolam and fluoxetine HCl 
(1000ug/ml each) were added with 1.0 ml drug-free plasma. The 
samples were incubated at RT (28 °C) for 2 h. Protein precipitation 
and extraction was carried out using acetonitrile (2 ml) and 
chloroform (4 ml) with vigorous vortex shaking for 2 min and 
centrifuged at 5000 rpm for 10 min. The organic phase was 
recovered and evaporated to dryness at RT. The residual mass was 
reconstituted with 10 ml methanol. Calibration standards (40-100 
ng/μl each) were prepared. Lastly, the quality control samples at 
three different concentration levels; Lower Limit of Quantitation 
LLOQ: 40 ng/μl; Low QC sample: 50 ng/μl; Middle QC sample: 70 
ng/μl; High QC sample: 100 ng/μl of both alprazolam and fluoxetine 
HCl respectively were prepared from the reconstituted solutions. A 
fixed volume (1μl) of the prepared standards were applied on TLC 
plates and developed under the optimized HPTLC conditions. 
Plasma sample preparation 
Fresh blood samples were withdrawn through the retro-orbital route 
of rats and collected in Eppendorf tubes previously rinsed with 
sodium citrate solution as an anti-coagulant. The blood samples were 
centrifuged at 5000 rpm for 15 min for separation of plasma. The 
separated plasma was employed for the study. Different solvents were 
tried for the extraction of alprazolam and fluoxetine HCl from plasma. 
Initially n-hexane, n-butanol were tried, but the sample recovery was 
very low. When chloroform (4 ml) was used, recovery was 
significantly improved. Acetonitrile was also added to increase the 
precipitation of plasma proteins. Finally, a mixture of acetonitrile and 
chloroform (2:4 v/v) was employed as the final solvent for extraction 
of alprazolam and fluoxetine HCl with good sample recovery. 
HPTLC chromatographic conditions 
254
Method validation 
 (0.25 mm thickness) 
on aluminium sheets were used as stationary phase. The mobile 
phase consisting of a mixture of ethyl acetate: toluene: methanol: 
ammonia (4:3:1:0.1, v/v/v/v) was used throughout the analysis. 
Plates were pre-washed using methanol as solvent and activated at 
120 °C for 30 min in hot air oven. Chamber saturation time was 
optimized at 20 min and plate development time was fixed at 10 min 
with migration distance of 8 cm. Slit dimension was constant at 5.0 x 
0.45 mm with a scan speed of 20 mm/s. From the overlain spectra of 
alprazolam and fluoxetine HCl, 230 nm was selected as the scanning 
wavelength for densitometric evaluation [14]. 
The developed method was validated as per the recommendations of 
USFDA Guidance for Industry: Bioanalytical Method Validation [15-16]. 
Selectivity was studied at the Lower Limit of Quantification (LLOQ) of 
40ng/μl by comparing the blank responses of plasma from six different 
sources with the peak areas afforded by the LLOQ samples.  
Accuracy and precision were studied by analyzing five replicates of 
the Lower Quality Control (LQC), Middle-Quality Control (MQC) and 
Higher Quality Control (HQC) samples. The concentration of 
alprazolam and fluoxetine HCl in the QC samples was determined by 
referring to the area ratio of the drug to standard drug dilution, 
obtained from the QC samples, the calibration equation generated on 
the same day. The accuracy was estimated as the mean % BIAS while 
the precision was measured in terms of % CV. The recovery of the 
extraction procedure was calculated by comparing the peak areas of 
the processed QC samples to those of corresponding standard 
dilutions.  
Stability was evaluated under various conditions viz. three freeze-
thaw cycles, stability at room temperature for 6 h and long-term 
stability at -20 °C for one week. For the determination of freeze-thaw 
stability, five replicates of LQC and HQC samples were frozen at -20 °C 
for a minimum of 24 h and then allowed to thaw unassisted at room 
temperature. For short-term room temperature stability, five 
replicates of LQC and HQC samples were kept at room temperature 
for 6 h. Long term stability at -20 °C for one week was determined 
by using five replicates of LQC and HQC. The precision and accuracy 
of stability samples was found, and the % CV and % BIAS were 
calculated [16-17]. 
RESULTS AND DISCUSSION 
Different mobile phase systems like ethyl acetate: toluene: 
methanol, ethyl acetate: toluene: methanol: glacial acetic acid, 
toluene: methanol: ammonia were tried in order to determine the 
best conditions for the effective separation of alprazolam and 
fluoxetine HCl. The mobile phase consisting of ethyl acetate: 
toluene: methanol: ammonia (4:3:1:0.1 v/v/v/v) was selected as it 
gave high resolution with compact spots at Rf value 0.48±0.04 and 
0.17±0.02 for alprazolam and fluoxetine HCl respectively. Also 
from the overlain spectra, it was observed that both alprazolam 
and fluoxetine HCl exhibited fairly good absorbance at about 230 




Linearity was established by analysing seven concentrations of 
alprazolam and fluoxetine HCl, both in the concentration range of 
40-100 ng/μl respectively, and then plotting the peak areas against 
the corresponding concentrations (table 1). 
  
Table 1: Assay parameters and regression characteristic of the binary mixture determined by the proposed method 
Parameters Alprazolam Fluoxetine HCl 
Wavelength (nm) 230 230 
Rf 0.48±0.04 0.17±0.02 
Concentration range  40-100 ng/µl 40-100 ng/µl 
Intercept(a) 215.757 31.242 
Sa 1.169 a 0.785 
Slope(b) 10.916 5.329 
Sb 1.110 b 0.888 
RSD% of slope 10.172 16.673 
r 0.9910 2 0.9932 
Regression equation: A= a+bc, where A is the absorbance, a is the intercept, b is the slope and c is the concentration. 
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Linearity of the calibration curves were validated by the high value 
of the regression coefficients (r>0.99).  
 
 
Fig. 2: 3D chromatogram of calibration standards (40-100 
ng/µl) for each drug detected at 230 nm 
The calibration range for the proposed method was established 
based on the reported pharmacokinetic data available in literature 
and the concentrations present in pharmaceutical products. Fig. 2 
represents the 3D chromatogram for each concentration detected at 
230 nm. 
Selectivity 
The selectivity of the method was investigated by analyzing blank 
rat plasma. The blank plasma sample was checked for its 
interference using the proposed liquid-liquid extraction procedure 
under the optimized HPTLC conditions and compared with a spiked 
sample concentration of alprazolam and fluoxetine HCl at LLOQ 
(40ng/μl) in rat plasma. There was no interference of the 
components of the biological matrix (plasma) in quantitation of both 
the drugs. 
Sensitivity 
During the validation studies, it was found that the peak areas for 
the LLOQ samples were more than five times the blank responses 
obtained using six different plasma sources, as shown in table 2.  
 
Table 2: Sensitivity data for ALP and FLU at LLOQ 
S. No. Nominal conc. (ng/µl) 
Alprazolam Fluoxetine HCl 
1 34.8 36.8 
2 41.2 36.3 
3 36.5 32.8 
4 37.0 39.0 
5 35.7 41.6 
Avg. 36.92 37.30 
SD 2.5645 3.2741 
% CV 6.94 8.77 
% Bias 6.57 6.45 
This proves that the method is selective at the LLOQ of 40ng/μl. The representative densitogram of blank plasma shows no interference at the Rf 
values of both drugs (fig. 3). The representative densitogram of alprazolam and fluoxetine HCl extracted from plasma at LLOQ is shown in fig. 4.  
 
 
Fig. 3: Densitogram of blank rat plasma 
 
 
Fig. 4: Typical densitogram of QC sample at LLOQ (40ng/µl) 
The lower limit of quantitation was found to be 36ng/and 37ng/μl 
for alprazolam and fluoxetine HCl respectively. The %CV was found 
to be 6.94% for alprazolam and 8.77% for fluoxetine HCl, % bias was 
found to be 6.57% and 6.45% for alprazolam and fluoxetine HCl 
respectively, and is within the acceptable limits. 
Precision and accuracy 
The evaluation of accuracy and precision showed that the % CV and 
% bias was less than ±15 as required by the USFDA Guidance 
guidelines. Precision of the method was determined by repeatability 
(intraday) and intermediate precision (inter-day)studies and 
accuracy for set of quality control (QC) samples at 40, 50, 70, 100 
ng/μl (LLOQ, LQC, MQC, HQC) in replicate (n = 5) (table 3). The 
coefficient of variance (%CV) and percent bias (%BIAS) were within 
the acceptable limits. The % BIAS was calculated using the formula:- 
% BIAS =
True conc.− Observed conc. (for both drugs)
True conc. (for both drugs)
× 100 
Recovery 
The recovery data was determined in triplicate at two 
concentrations (LQC and HQC) as recommended by FDA guidelines. 
The recovery at these two concentrations, 50 and 100 ng/μl was 
found to be 87.10%, 94.42% for alprazolam and 87.42%, 93.29% for 
fluoxetine HCl (table 3). The % recovery was calculated using 
following formula:- 
% Recovery =  
Area of fresh extracted sample (both drugs)




From the stability studies, it was observed that the % CV and % RSD 
was less than 15, as shown in table 4, which falls within the 
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acceptable limits. This indicates that the deviation of the results 
from nominal concentration may be attributed to the variability of 
the assay and implies that the drugs are stable after the stability 
cycles.
 
Table 3: Assessment of the accuracy, precision and % recovery of Alprazolam and Fluoxetine HCl 
Level Alprazolam Fluoxetine HCl 
LLOQ LQC MQC HQC LLOQ LQC MQC HQC 
Conc. 40 50 70 100 40 50 70 100 
Intra 
day  
Mean conc.* (ng/band)  35.66 44.76 65.56 95.36 37.30 44.56 62.7 94.65 
% CV 2.16 2.03 2.67 1.99 8.77 3.99 3.32 3.40 
% Bias 11.00 10.48 6.42 4.40 6.45 11.2 10.4 5.35 
Inter 
day  
Mean conc.* (ng/band)  37.08 45.9 66.14 95.66 36.92 45.64 65.26 96.28 
% CV 3.35 4.38 1.95 1.62 6.94 4.48 3.35 3.64 
% Bias 7.42 8.20 5.51 4.34 6.57 8.72 6.77 3.72 
% Recovery* - 87.10 - 94.42 - 87.42 - 93.29 
*n = 5 
 
Table 4: Results of stability studies for alprazolam and fluoxetine HCl 
Stability study Alprazolam Fluoxetine HCl 
*LQC *HQC *LQC *HQC 
Short term stability % CV 1.48 3.97 2.76 2.01 
% Bias 8.86 3.18 10.28 2.82 
Freeze thaw stability % CV 1.27 1.12 2.37 1.65 
% Bias 12.9 2.24 9.48 4.16 
Long term stability % CV 4.30 1.76 1.45 1.01 
% Bias 9.84 1.24 9.20 2.82 
*n = 5 
 
The results of the study indicated that the proposed HPTLC-UV 
method has a high degree of sensitivity, selectivity with an 
acceptable degree of accuracy and precision. As there are no 
reported methods for the simultaneous estimation of these two 
drugs in biological fluids, the developed method can prove to be 
suitable for such applications. 
CONCLUSION 
The present work presents a simple, rapid, sensitive and economical 
method for determination of alprazolam and fluoxetine HCl in rat 
plasma. A good separation of the analytes in this combination was 
achieved by using the mobile phase containing ethyl acetate: 
toluene: methanol: ammonia (4:3:1:0.1 v/v/v/v). The method 
utilizes protein precipitation with liquid-liquid extraction using a 
mixture of acetonitrile and chloroform as the only sample 
preparation step prior to HPTLC analysis. The rapid, single step, 
sample preparation coupled with the simple HPTLC-UV 
chromatographic conditions makes the method cost effective and 
suitable for analysis of a large number of plasma samples containing 
the drugs. The method was fully validated to meet the requirements 
for linearity, sensitivity, accuracy and precision as per US FDA 
guidelines. The method can be suitably employed for the 
bioavailability and bioequivalence study of alprazolam and 
fluoxetine HCl. 
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